Member Info for Early_Bird

then up we go again. 20% under IPO price still but I feel that wont be the case for much longer.

Something is certainly hoovering up all the sells. Lovely and tallies with what ive been hearing.

I thought IPO 24p was cheap!

Only other EB competitor bought out for $842m when commencing P3 trials. Theyve have now been delayed. AMYT starts its P3 Q1. AMYT (Birken) has already done prelim trials showing Episalvan is effective in treating EB. Its also got a USP over its $842 competitor where it only needs to be applied every time they change their dressings and not every day (which seems totally impractical) Med term potential: 20 bags. Say what you will... the BOD here are the best ive come across on AIM and Mr Stratford came out of retirement to get involved, this dragon knows a winner when he sees one.

of 24p this month prior to expectation of newsflow. Those getting in now have themselves a bargain.

you said it mate :) This is a lifechanging opportunity in the making.

this to be over 2p by the time news lands. Had some very interesting correspondence here recently. Brett comes across very professional and extremely driven to succeed with this.

think they must have plit a trade in to smaller ones then reversed it and done it in one chunk?? All v odd. SP blue so not complaining.

Fully expecting institutional buying here from what im hearing so could well be the start of it.

L2 sea of blue

fully cashed up until P3 trials are finished and before then im expecting buyout... so risk is minimal. Also Cathal stated back when MC was over �40m that they could sell Epislvan right now for much more than current MC.

Indeed Cookie its looking rather encouraging isnt it. More of a foregone conclusion... TBH with the likes of Harry Stratford coming out of retirement to get involved it must be something special. Market will catch on here and when it does we are talking many many multiples of this. Am v patient with this one.

since listing"... a question that lots in and on the side lines are wondering.... https://www.youtube.com/watch?v=3xvETqoMrwQ&feature=youtu.be From the horses mouth CFs response 18mins in. News flow about to start. SP on floor. Great buy op.

Shire Pharma's Market cap being 1500 bags higher than AMYT....

Also worth watching is the first video on my list below between 8mins & 10 mins where Rory shows on his slide that Birken (company that Amrty acquired) have already completed some prelim EB studies prior to them starting their P3 studies for partial thickness wounds where Episalvan was shown to be effective in treating EB.... So join the dots.... Adding to that we have very strong links with Shire (worlds largest Orphan drug company), Harry Startford the founder of Shire came out of retirement to get involved with Amryt.

That's imminent... 3 piece in my mind that could land in the nearterm: - Commencement of Episalvan tox studies for EB (3 month study that proceeds P3 trials that are due to start beginning 2017, therefore expect this to start imminently) - Nasdaq listing application (process takes 6-12months and they have stated that they hope to be fully listed Q2 2017) - Imlan product marketing update. Remember we have Mr Sudocrem on the board here so market positioning for this product could catch the market by surprise. Rememer it did 1m Euros revenue with zero marketing... Regarding the second bullet point above, make reference to the second video on my previous post, between 7mins & 9mins..... hence why I say not long until the traction starts here. Huge potential and sooner than most people are expecting.

All these Amryt presentations and webinars worth a watch to give a picture of of the size of the beast we are dealing with here. https://www.youtube.com/watch?v=6J1VDzlahW0 https://www.youtube.com/watch?v=3xvETqoMrwQ&feature=youtu.be https://www.youtube.com/watch?v=iO8RHVgsgMg http://media.investis.com/a/amryt/amryt.mp4

Haha those 3 extra bags are v important! IPO here 24p, those buying in now get that chance of making 50% profit before this even reaches IPO price again where most holders are in at. I hold all of my 24p IPO shares and have been adding more recently at these levels. Golden opportunity.

Expecting big movement here Q4 and Q1 '17 Nasdaq listing news and P3 trials commencing could see this one keep running and running. The only other EB competitor got bought out on the strength of its phase 2b trials for circa $840m, a drug that required daily application (not really very practical). Amyt's Episalvan starts P3 trials q1 and application only every few days when they change their dressings (practical). We have very strong links to Shire so im sure they are watching with interest. $840m hmm thats... 22 bags from current levels...... some upside indeed! Fully funded until completion of P3 so I really dont see any risk whatsoever from these levels.

Indeed the 75m Bass shares (7.5% of Bass) that STGR will be getting initially at $0.01 are already worth 40% more. What interests me also are the hints of what they are lining up ready for the first tranch of cash. Due diligence has been done.